136 related articles for article (PubMed ID: 37975796)
1. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis-insights from a completed randomized controlled trial with rasagiline.
Witzel S; Statland JM; Steinacker P; Otto M; Dorst J; Schuster J; Barohn RJ; Ludolph AC
Eur J Neurol; 2024 Mar; 31(3):e16154. PubMed ID: 37975796
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
[TBL] [Abstract][Full Text] [Related]
4. Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: A longitudinal follow-up study.
Chen PC; Wu D; Hu CJ; Chen HY; Hsieh YC; Huang CC
J Neurol Sci; 2020 Nov; 418():117070. PubMed ID: 32836016
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.
Witzel S; Frauhammer F; Steinacker P; Devos D; Pradat PF; Meininger V; Halbgebauer S; Oeckl P; Schuster J; Anders S; Dorst J; Otto M; Ludolph AC
Transl Neurodegener; 2021 Aug; 10(1):31. PubMed ID: 34433481
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Shi J; Qin X; Chang X; Wang H; Guo J; Zhang W
J Cell Mol Med; 2022 Jan; 26(2):583-587. PubMed ID: 34866307
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.
Statland JM; Moore D; Wang Y; Walsh M; Mozaffar T; Elman L; Nations SP; Mitsumoto H; Fernandes JA; Saperstein D; Hayat G; Herbelin L; Karam C; Katz J; Wilkins HM; Agbas A; Swerdlow RH; Santella RM; Dimachkie MM; Barohn RJ;
Muscle Nerve; 2019 Feb; 59(2):201-207. PubMed ID: 30192007
[TBL] [Abstract][Full Text] [Related]
10. Significance of CSF NfL and tau in ALS.
Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis.
Verde F; Steinacker P; Weishaupt JH; Kassubek J; Oeckl P; Halbgebauer S; Tumani H; von Arnim CAF; Dorst J; Feneberg E; Mayer B; Müller HP; Gorges M; Rosenbohm A; Volk AE; Silani V; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):157-164. PubMed ID: 30309882
[TBL] [Abstract][Full Text] [Related]
12. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
[TBL] [Abstract][Full Text] [Related]
13. Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice.
Benatar M; Ostrow LW; Lewcock JW; Bennett F; Shefner J; Bowser R; Larkin P; Bruijn L; Wuu J
Ann Neurol; 2024 Feb; 95(2):211-216. PubMed ID: 38110839
[TBL] [Abstract][Full Text] [Related]
14. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
[TBL] [Abstract][Full Text] [Related]
16. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.
Macchi Z; Wang Y; Moore D; Katz J; Saperstein D; Walk D; Simpson E; Genge A; Bertorini T; Fernandes JA; Swenson A; Elman L; Dimachkie M; Herbelin L; Miller J; Lu J; Wilkins H; Swerdlow RH; Statland J; Barohn R;
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):345-52. PubMed ID: 25832828
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis.
Tortelli R; Copetti M; Ruggieri M; Cortese R; Capozzo R; Leo A; D'Errico E; Mastrapasqua M; Zoccolella S; Pellegrini F; Simone IL; Logroscino G
Eur J Neurol; 2015 Jan; 22(1):215-8. PubMed ID: 24750431
[TBL] [Abstract][Full Text] [Related]
18. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis.
Falzone YM; Domi T; Mandelli A; Pozzi L; Schito P; Russo T; Barbieri A; Fazio R; Volontè MA; Magnani G; Del Carro U; Carrera P; Malaspina A; Agosta F; Quattrini A; Furlan R; Filippi M; Riva N
Eur J Neurol; 2022 Jul; 29(7):1930-1939. PubMed ID: 35263489
[TBL] [Abstract][Full Text] [Related]
19. Plasma neurofilament light levels show elevation two years prior to diagnosis of amyotrophic lateral sclerosis in the UK Biobank.
Smith EN; Lee J; Prilutsky D; Zicha S; Wang Z; Han S; Zach N
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):170-176. PubMed ID: 38013452
[TBL] [Abstract][Full Text] [Related]
20. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.
Gille B; De Schaepdryver M; Goossens J; Dedeene L; De Vocht J; Oldoni E; Goris A; Van Den Bosch L; Depreitere B; Claeys KG; Tournoy J; Van Damme P; Poesen K
Neuropathol Appl Neurobiol; 2019 Apr; 45(3):291-304. PubMed ID: 29908069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
